Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.

• Status: Completed
• Trial end date: 2008-04-04
• Target enrollment: 0
• Participant gender: All

Summary

This study will use scintigraphy techniques to measure gastric emptying rate of liquid and solid food at baseline and after administration of GSK716155 or placebo.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: rGLP-1 protein

Criteria

Inclusion Criteria:

• Healthy men or women, between the ages of 18 and 65, and have a Body Mass Index (BMI) of between 20 and 32.

• If female, the subject must be not be capable of having children.

Exclusion Criteria:

• Subjects must not use tobacco, nicotine, or illegal drugs of abuse, and must not take caffeine or alcohol for 24 hours before dosing and before each set of scintigraphy procedures.

• Subjects may not have HIV, hepatitis, elevated fasting blood sugar levels, high blood pressure, heart, lung, liver, gall bladder, gastrointestinal, pancreatic, or kidney disease, or untreated thyroid disease.

• Subjects must not have a history of alcohol abuse, must not take prescription or non-prescription drugs within 7 days of Day 1 and Day 8 of the study, and must not have previous exposure to any GLP-1 mimetic or exenatide.

• Prior radiation exposures must meet certain limits in order to participate in this study.